Organisms | Evidence |
---|---|
Ovis aries (sheep) | |
Cricetulus griseus (Chinese hamster) | |
Mus musculus (house mouse) | |
Bos taurus (domestic cattle) | |
Escherichia coli |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
---|---|---|---|---|
GCNT1 | UDP-GlcNAc |
|
[alpha]-1-p-nitrophenyl | |
GCNT4 | UDP-GlcNAc |
|
[alpha]-1-p-nitrophenyl | |
GCNT3 | UDP-GlcNAc |
|
[alpha]-1-p-nitrophenyl | |
B3GNT8 | UDP-GlcNAc |
|
[alpha]-pNp | |
B3GNT2 | UDP-GlcNAc |
|
[alpha]1-OBn |
Pathway Name | Organism |
---|---|
E.coli O101 | Escherichia coli |
E.coli O103 | Escherichia coli |
E.coli O107 | Escherichia coli |
E.coli O112ab | Escherichia coli |
E.coli O112ac | Escherichia coli |
E.coli O116 | Escherichia coli |
E.coli O117 | Escherichia coli |
E.coli O125ab | Escherichia coli |
E.coli O127 | Escherichia coli |
E.coli O128ab-H27 | Escherichia coli |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
29665849 | An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides | Eggink LL | 2018 Apr 17 |
|
29894213 | Low-glycosylated forms of both FSH and LH play major roles in the natural ovarian stimulation | Wide L | 2018 Apr 03 |
|
28774839 | pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes | Hashiba K | 2017 Sep 28 |
|
28922551 | Lectin BS‐I inhibits cell migration and invasion via AKT/GSK‐3β/β‐catenin pathway in hepatocellular carcinoma | Jian Q | 2017 Sep 18 |
|
28981809 | Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates | Nair JK | 2017 Sep 15 |
|
28785176 | Predicting the Retention Behavior of Specific O-Linked Glycopeptides | Badgett MJ | 2017 Sep |
|
29069408 | Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes | Tanowitz M | 2017 Oct 23 |
|
28709621 | Role of N-acetyl galactosamine-4-SO4, a ligand of CD206 in HSV-induced mouse model of Behçet's disease | Choi B | 2017 Oct 15 |
|
28921968 | Automated Solid-Phase Click Synthesis of Oligonucleotide Conjugates: From Small Molecules to Diverse N-Acetylgalactosamine Clusters | Farzan VM | 2017 Oct 04 |
|
28986168 | Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus | Sato Y | 2017 Nov 28 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025